Who are Celldex Therapeutics, Inc.'s main suppliers?

Celldex Therapeutics, Inc. (CLDX) key suppliers include: CDMOS, LEERINK-PARTNERS-LLC, TD-SECURITIES-USA-LLC, iBio, Inc., Pyxis Oncology, Inc. and 2 more. View the full supplier network at chainsifter.com/chain/CLDX.

Who are Celldex Therapeutics, Inc.'s major customers?

Celldex Therapeutics, Inc. (CLDX) key customers include: ROCKEFELLER-UNIVERSITY, Pyxis Oncology, Inc., Arcus Biosciences, Inc., Sanofi, Sanofi and 1 more. View the full customer network at chainsifter.com/chain/CLDX.

What sector is Celldex Therapeutics, Inc. in?

Celldex Therapeutics, Inc. (CLDX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Celldex Therapeutics, Inc. Supplier List (CLDX): 7 Verified Suppliers

7Suppliers

6Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Celldex Therapeutics, Inc. (CLDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

3Distinct source URLs

6High confidence

0.789Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Celldex Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CDMOS	CDMOS	92%	We rely on CDMOs over whom we have limited control. Should the cost, delivery and quality of clinical materials manufactured by us in our Fall River facility or supplied by CDMOs vary to our disadvan…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	92%	On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
TD-SECURITIES-USA-LLC	TD-SECURITIES-USA-LLC	92%	On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri…
PYXS	Pyxis Oncology, Inc.	72%	Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS g…
SEPN	Septerna, Inc.	72%	Reciprocal relationship from SEPN graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties …

Celldex Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
ROCKEFELLER-UNIVERSITY	ROCKEFELLER-UNIVERSITY	90%	The Company recognized $ 0.0 million and $ 0.6 million in revenue under the agreements with Rockefeller during the three months ended March 31, 2026, and 2025, respectively.
PYXS	Pyxis Oncology, Inc.	72%	Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation deci…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYN…
SNYNF	Sanofi	72%	gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drugs or import bans. The regulatory requirements and policies may change and additiona…
KOLLTAN-PHARMACEUTICALS-INC	KOLLTAN-PHARMACEUTICALS-INC	62%	ce obligations in the contract; and ● Recognition of revenue when, or as, the Company satisfies a performance obligation. Revenue for the Company is derived from product development agreements with c…

Celldex Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CLDX-DEBT	Debt stack $1.9M	90%	Market cache reports total debt of $1.9M.

Celldex Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CLDX-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP	WELLINGTON MANAGEMENT GROUP LLP	90%	13F overlay lists WELLINGTON MANAGEMENT GROUP LLP as top holder; 232 tracked holders.

Celldex Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
CTMX	CytomX Therapeutics, Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
BBIO	BridgeBio Pharma, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
GRDX	GridAI Technologies Corp.	100.00	2

Celldex Therapeutics, Inc. Supply Chain